Xenon Pharmaceuticals Advances Azetukalner Regulatory Path and Announces X-FIRST Study Timeline
Xenon Pharmaceuticals (XENE) is progressing with its lead candidate, azetukalner (AZK), as it moves toward a potential FDA New Drug Application (NDA) for the treatment of focal seizures. CEO Ian Mortimer emphasized that the company's strategic focus remains on securing U.S. approval and launch while simultaneously exploring broader therapeutic applications for the drug. The company maintains a strong liquidity position, with approximately $1.2 billion in cash expected to fund operations through 2029. Additionally, Xenon has outlined plans to initiate its X-FIRST study in the first quarter of 2027, marking a significant step in its clinical development pipeline.
Tickers: $XENE
Topics: clinical development drug development FDA approval pipeline focal seizures